Top

Published in:

01-12-2019 | Original article

rAAV6-mediated miR-29b delivery suppresses renal fibrosis

Authors: Suguru Saito, Shin-ichiro Ohno, Yuichirou Harada, Keiki Oikawa, Koji Fujita, Shouichirou Mineo, Asako Gondo, Yoshihiko Kanno, Masahiko Kuroda

Published in: Clinical and Experimental Nephrology | Issue 12/2019

Abstract

Background

Previous studies showed that microRNA-29b (miR-29b) inhibits renal fibrosis. Therefore, miR-29b replacement therapy represents a promising approach for treating renal fibrosis. However, an efficient method of kidney-targeted miRNA delivery has yet to be established. Recombinant adeno-associated virus (rAAV) vectors have great potential for clinical application. For kidney-targeted gene delivery, the most suitable AAV serotype has yet to be established. Here, we identified the most suitable AAV serotype for kidney-targeted gene delivery and determined that AAV-mediated miR-29b delivery can suppress renal fibrosis in vivo.

Method

To determine which AAV serotype is suitable for kidney cells, GFP-positive cells were identified by flow cytometry after the infection of rAAV serotype 1–9 vectors containing the EGFP gene. Next, we injected rAAV vectors into the renal pelvis to determine transduction efficiency in vivo. GFP expression was measured seven days after injecting rAAV serotype 1–9 vectors carrying the EGFP gene. Finally, we investigated whether rAAV6-mediated miR-29b delivery can suppress renal fibrosis in UUO mouse model.

Results

We found that rAAV6 vector is the most suitable for targeting kidney cells regardless of animal species in vitro and rAAV6 is the most suitable vector for kidney-targeted in vivo gene delivery in mice. Intra-renal pelvic injection of rAAV vectors can transduce genes into kidney TECs. Furthermore, rAAV6-mediated miR-29b delivery attenuated renal fibrosis in UUO model by suppressing Snail1 expression.

Conclusion

Our study has revealed that rAAV6 is the most suitable serotype for kidney-targeted gene delivery and rAAV6-mediated miR-29b delivery into kidney TECs can suppress established renal fibrosis.

Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684–96. https://doi.org/10.1038/nrneph.2011.149.CrossRefPubMedPubMedCentral

Grande MT, Sanchez-Laorden B, Lopez-Blau C, De Frutos CA, Boutet A, Arevalo M, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015;21(9):989–97. https://doi.org/10.1038/nm.3901.CrossRefPubMed

Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015;21(9):998–1009. https://doi.org/10.1038/nm.3902.CrossRefPubMedPubMedCentral

Zhou D, Liu Y. Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12(2):68–70. https://doi.org/10.1038/nrneph.2015.215.CrossRefPubMed

LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19(8):1047–53. https://doi.org/10.1038/nm.3218.CrossRefPubMedPubMedCentral

Borges FT, Melo SA, Ozdemir BC, Kato N, Revuelta I, Miller CA, et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 2013;24(3):385–92. https://doi.org/10.1681/ASN.2012101031.CrossRefPubMed

Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44(4):237–44. https://doi.org/10.1152/physiolgenomics.00141.2011.CrossRefPubMedPubMedCentral

Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011;22(8):1462–74. https://doi.org/10.1681/ASN.2010121308.CrossRefPubMedPubMedCentral

Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23(2):252–65. https://doi.org/10.1681/ASN.2011010055.CrossRefPubMedPubMedCentral

10.

Chen HY, Zhong X, Huang XR, Meng XM, You Y, Chung AC, et al. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther. 2014;22(4):842–53. https://doi.org/10.1038/mt.2013.235.CrossRefPubMedPubMedCentral

11.

Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997;3(3):306–12.CrossRefPubMed

12.

Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93(24):14082–7.CrossRefPubMedPubMedCentral

13.

Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15(7):445–51. https://doi.org/10.1038/nrg3742.CrossRefPubMedPubMedCentral

14.

Smalley E. First AAV gene therapy poised for landmark approval. Nat Biotechnol. 2017;35(11):998–9. https://doi.org/10.1038/nbt1117-998.CrossRefPubMed

15.

Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1(1):427–51. https://doi.org/10.1146/annurev-virology-031413-085355.CrossRefPubMed

16.

Muramatsu S, Mizukami H, Young NS, Brown KE. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology. 1996;221(1):208–17.CrossRefPubMed

17.

Ito K, Chen J, Khodadadian JJ, Vaughan ED, Lipkowitz M, Poppas DP, et al. Adeno-associated viral vector transduction of green fluorescent protein in kidney: effect of unilateral ureteric obstruction. BJU Int. 2008;101(3):376–81. https://doi.org/10.1111/j.1464-410X.2007.07313.x.CrossRefPubMed

18.

Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73. https://doi.org/10.1158/1535-7163.MCT-12-0100.CrossRefPubMed

19.

Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 2004;32(3):1154–8. https://doi.org/10.1093/nar/gkh278.CrossRefPubMedPubMedCentral

20.

Kida Y, Sato T. Tubular changes in obstructed kidney of adult mice evaluated using immunohistochemistry for segment-specific marker. Histol Histopathol. 2007;22(3):291–303. https://doi.org/10.14670/HH-22.291.CrossRefPubMed

21.

Takeda S, Takahashi M, Mizukami H, Kobayashi E, Takeuchi K, Hakamata Y, et al. Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1–5 vectors in vitro and in vivo. Nephron Exp Nephrol. 2004;96(4):e119–e12626. https://doi.org/10.1159/000077378.CrossRefPubMed

22.

Rocca CJ, Ur SN, Harrison F, Cherqui S. rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther. 2014;21(6):618–28. https://doi.org/10.1038/gt.2014.35.CrossRefPubMedPubMedCentral

23.

Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073–80. https://doi.org/10.1038/mt.2008.76.CrossRefPubMed

24.

Kotterman MA, Schaffer DV. Engineered AAV vectors for improved central nervous system gene delivery. Neurogenesis (Austin). 2015;2(1):e1122700. https://doi.org/10.1080/23262133.2015.1122700.CrossRef

25.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

Title: rAAV6-mediated miR-29b delivery suppresses renal fibrosis
Authors: Suguru Saito
Shin-ichiro Ohno
Yuichirou Harada
Keiki Oikawa
Koji Fujita
Shouichirou Mineo
Asako Gondo
Yoshihiko Kanno
Masahiko Kuroda
Publication date: 01-12-2019
Publisher: Springer Singapore
Published in: Clinical and Experimental Nephrology / Issue 12/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-019-01783-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

rAAV6-mediated miR-29b delivery suppresses renal fibrosis

Abstract

Background

Method

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2019

Clinicopathological analysis of ANCA-associated glomerulonephritis focusing on plasma cell infiltrate

A clinicopathological comparison between IgA nephropathy and Henoch–Schönlein purpura nephritis in children: use of the Oxford classification

List of referees

Low birth weight is associated with decline in renal function in Japanese male and female adolescents

Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study

Ratio of triglyceride to high-density lipoprotein cholesterol and risk of major cardiovascular events in kidney transplant recipients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page